Editas Medicine(EDIT) - 2024 Q4 - Annual Results

CAMBRIDGE, Mass., Jan. 13, 2025 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of concept data in non- human primates editing hematopoietic stem cells (HSCs) and liver cells and in vivo delivery data in humanized mice to two additional target cell types. "Two years ago, we detailed our objective ...